6月22日，艾伯维盘中上涨3.24%，报226.555美元/股，成交额1.97亿美元。
消息面上，艾伯维正式宣布以每股135.11美元全现金收购抗炎药物研发商Apogee Therapeutics，总股权价值约109亿美元，较Apogee此前收盘价溢价约60%。这是艾伯维五年多来规模最大的收购。公司CEO表示该交易与构建产品管线、为2030年代以后增添新增长动力的战略"绝佳契合"。
此次收购将把Apogee核心候选药物zumilokibart纳入艾伯维免疫学产品线。该产品线由修美乐、喜达诺和林沃克领衔，去年合计创收304亿美元，同比增长约14%。市场对交易反应积极，Apogee盘前大涨近47%。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.